<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A08A&quot;,&quot;href&quot;:&quot;atc/A08A.md&quot;},{&quot;label&quot;:&quot;sibutramine&quot;}]"></div>

# sibutramine

- **generic name:** sibutramine
- **ATC codes:** `A08AA10`
- **DrugBank:** [DB01105](https://go.drugbank.com/drugs/DB01105) · **PubChem:** [CID 5210](https://pubchem.ncbi.nlm.nih.gov/compound/5210)
- **molar mass:** 279.848 g/mol (C17H26ClN) — DrugBank
- **groups:** approved, illicit, withdrawn

## About

Sibutramine is a centrally acting antiobesity drug that was used to help reduce obesity. It has been withdrawn and is now considered a banned substance, so it is no longer in medical use.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q424151](https://www.wikidata.org/wiki/Q424151) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-04 21:13 | 2:17 | 0/0/0 | 1/0/0 | 0/0/0 | 71,930/3,639 | ollama / qwen3.8:27b-mtp-q8_0 | 6 | 0/4 | 6/0 | 0 |

## popPK records

_not available_

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> <span class="pk-badge pk-badge--species" title="Animal study (dog), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">dog</span> | [Yun_2015_hERG](drugs/drug_sibutramine/pd_Yun_2015_hERG.md) | hERG channel current ← sibutramine · direct sigmoid Emax (Hill) effect | — | Yun J et al., Cardiovascular Safety Pharmacology of S…, Biomolecules & therapeutics (2015) | [10.4062/biomolther.2015.033](https://doi.org/10.4062/biomolther.2015.033) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=sibutramine) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |
| metabolism | liver | `CYP3A4` substrate | DrugBank actor |
| metabolism | small intestine | `CYP3A4` substrate | DrugBank actor |
| excretion | bile duct | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | liver | <sub>named in DrugBank's ADME text</sub> | prose |
| — | brain | `SLC6A4` inhibitor | DrugBank actor |
| — | platelet | `SLC6A4` inhibitor | DrugBank actor |

<sub>Actors without a tissue in the table: SLC6A2 (inhibitor), SLC6A3 (inhibitor).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 72 matched, 69 returned
- **screened:** 0  ·  **relevant:** 0
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_14 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Bae_2013.pdf` | Bae SH et al., Potent inhibition of cytochrome P450 2B…, Chemico-biological interact… (2013) | pd | 4 | [10.1016/j.cbi.2013.06.006](https://doi.org/10.1016/j.cbi.2013.06.006) | [23777987](https://www.ncbi.nlm.nih.gov/pubmed/23777987) | metadata signals extractable PD data (IC50) |
| `Kim_2007.pdf` | Kim SE et al., Open channel block of A-type, kv4.3, an…, The Journal of pharmacology… (2007) | pd | 4 | [10.1124/jpet.106.117747](https://doi.org/10.1124/jpet.106.117747) | [17312186](https://www.ncbi.nlm.nih.gov/pubmed/17312186) | metadata signals extractable PD data (IC50) |
| `Kim_2008.pdf` | Kim KS et al., Electrophysiological safety of sibutram…, Human & experimental toxico… (2008) | pd | 4 | [10.1177/0960327108095991](https://doi.org/10.1177/0960327108095991) | [18829731](https://www.ncbi.nlm.nih.gov/pubmed/18829731) | metadata signals extractable PD data (IC50) |
| `Lu_2024.pdf` | Lu N et al., Enzyme-linked immunoassay for simultane…, Analytical methods : advanc… (2024) | pd | 4 | [10.1039/d4ay00879k](https://doi.org/10.1039/d4ay00879k) | [38873980](https://www.ncbi.nlm.nih.gov/pubmed/38873980) | metadata signals extractable PD data (IC50) |
| `Bae_2011.pdf` | Bae JW et al., Effects of clopidogrel on the pharmacok…, Journal of clinical pharmac… (2011) | pgx | 8 | [10.1177/0091270010388651](https://doi.org/10.1177/0091270010388651) | [21209232](https://www.ncbi.nlm.nih.gov/pubmed/21209232) | metadata signals extractable PGX data (CYP2B6, PK/PD-context) |
| `Chetty_2021.pdf` | Chetty M et al., Clopidogrel Dosing: Current Successes a…, Clinical pharmacology and t… (2021) | pgx | 8 | [10.1002/cpt.2055](https://doi.org/10.1002/cpt.2055) | [32970826](https://www.ncbi.nlm.nih.gov/pubmed/32970826) | metadata signals extractable PGX data (CYP2C19, PK/PD-context) |
| `Chung_2011.pdf` | Chung JY et al., Effect of CYP2B6 genotype on the pharma…, Journal of clinical pharmac… (2011) | pgx | 8 | [10.1177/0091270010362906](https://doi.org/10.1177/0091270010362906) | [20350955](https://www.ncbi.nlm.nih.gov/pubmed/20350955) | metadata signals extractable PGX data (CYP2B6, PK/PD-context) |
| `Hwang_2014.pdf` | Hwang IC et al., Effects of CYP3A5, CYP2C19, and CYP2B6…, Clinica chimica acta; inter… (2014) | pgx | 8 | [10.1016/j.cca.2013.11.007](https://doi.org/10.1016/j.cca.2013.11.007) | [24262967](https://www.ncbi.nlm.nih.gov/pubmed/24262967) | metadata signals extractable PGX data (CYP3A5, PK/PD-context) |
| `Kim_2009.pdf` | Kim KA et al., Association of CYP2B6, CYP3A5, and CYP2…, Clinical pharmacology and t… (2009) | pgx | 8 | [10.1038/clpt.2009.145](https://doi.org/10.1038/clpt.2009.145) | [19693007](https://www.ncbi.nlm.nih.gov/pubmed/19693007) | metadata signals extractable PGX data (CYP2B6, PK/PD-context) |
| `Pan_2013.pdf` | Pan W et al., Effects of clopidogrel and clarithromyc…, Xenobiotica; the fate of fo… (2013) | pgx | 8 | [10.3109/00498254.2012.706722](https://doi.org/10.3109/00498254.2012.706722) | [22830954](https://www.ncbi.nlm.nih.gov/pubmed/22830954) | metadata signals extractable PGX data (CYP2B6*6, PK/PD-context) |
| `Shinde_2013.pdf` | Shinde DD et al., Different effects of clopidogrel and cl…, Journal of clinical pharmac… (2013) | pgx | 8 | [10.1002/jcph.69](https://doi.org/10.1002/jcph.69) | [23381968](https://www.ncbi.nlm.nih.gov/pubmed/23381968) | metadata signals extractable PGX data (CYP2B6, PK/PD-context) |
| `Bailey_2004.pdf` | Bailey DG et al., Interactions between grapefruit juice a…, American journal of cardiov… (2004) | pgx | 7 | [10.2165/00129784-200404050-00002](https://doi.org/10.2165/00129784-200404050-00002) | [15449971](https://www.ncbi.nlm.nih.gov/pubmed/15449971) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Shinde_2014.pdf` | Shinde DD et al., Enantioselective N-demethylation and hy…, Journal of toxicology and e… (2014) | pgx | 7 | [10.1080/15287394.2014.951758](https://doi.org/10.1080/15287394.2014.951758) | [25343291](https://www.ncbi.nlm.nih.gov/pubmed/25343291) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Bae_2008.pdf` | Bae SK et al., Cytochrome P450 2B6 catalyzes the forma…, Drug metabolism and disposi… (2008) | pgx | 5 | [10.1124/dmd.108.020727](https://doi.org/10.1124/dmd.108.020727) | [18474675](https://www.ncbi.nlm.nih.gov/pubmed/18474675) | metadata signals extractable PGX data (CYP2B6) |

<sub>queue written 2026-10-04T21:11:48.787021+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PGx | Bae_2008 | not_relevant | 2 | 0 | The paper identifies CYP2B6 as the enzyme responsible for sibutramine metabolism in vitro but does not report any pharmacogenomic data (genotype-phenotype associations) or changes in PK/PD parameters based on genetic variants. |
| PGx | Bae_2011 | not_relevant | 0 | 0 | The study investigates a drug-drug interaction (clopidogrel inhibiting CYP enzymes) rather than a pharmacogenomic effect of a specific gene variant on sibutramine PK. |
| popPK | Bae_2013 | irrelevant | 0 | 0 | The paper describes in-vitro mechanistic studies of CYP2B6 inhibition and does not report quantitative pharmacokinetic disposition parameters for sibutramine. |
| PD | Bae_2013 | not_relevant | 0 | 0 | The paper reports in vitro enzyme inhibition kinetics (IC50/Ki) for CYP2B6, which is a pharmacokinetic/metabolic parameter, not a pharmacodynamic exposure-response or dose-response relationship for a clinical effect. |
| PGx | Bae_2013 | not_relevant | 0 | 0 | The paper investigates the in vitro inhibition of CYP2B6 by sibutramine, not the effect of a genetic variant on sibutramine's PK or PD. |
| PGx | Bailey_2004 | not_relevant | 0 | 0 | The paper discusses drug-food interactions (grapefruit juice) and does not report any pharmacogenomic effects (gene variants) on sibutramine PK/PD. |
| popPK | Balcioglu_2000 | irrelevant | 0 | 0 | The study is a neuropharmacological investigation of brain dopamine and serotonin levels using microdialysis and in-vitro uptake assays, reporting no systemic pharmacokinetic parameters such as clearance, volume, or half-life. |
| popPK | Berkowitz_2006 | irrelevant | 0 | 0 | The study is a clinical trial assessing weight loss efficacy and safety, reporting no pharmacokinetic parameters such as clearance, volume, or half-life. |
| popPK | Blumenthal_2014 | irrelevant | 0 | 0 | The study is an electronic health records analysis of weight gain associated with antidepressants, where sibutramine is used only as a comparator for assay sensitivity, and no pharmacokinetic parameters are reported. |
| PGx | Chetty_2021 | not_relevant | 0 | 0 | The paper discusses clopidogrel pharmacogenomics and mentions sibutramine only as a CYP2B6 substrate affected by clopidogrel co-administration, not as the primary drug with a reported genetic effect. |
| popPK | Franco_2009 | irrelevant | 2 | 0 | The study reports only bioequivalence ratios (CIs) and non-compartmental AUC/Cmax, lacking specific quantitative disposition parameters like clearance, volume, or half-life. |
| PGx | Gong_2018 | not_relevant | 0 | 0 | The paper investigates herb-drug interactions (CYP inhibition by sauchinone) and does not report any pharmacogenomic effects (gene variants) on sibutramine PK/PD. |
| popPK | Gray_1998 | irrelevant | 0 | 0 | The paper is a pharmacodynamic study investigating the antinociceptive mechanism of antidepressants in mice and does not report any pharmacokinetic parameters for sibutramine. |
| popPK | Grilo_2015 | irrelevant | 0 | 0 | The paper is a clinical trial evaluating the efficacy of sibutramine for binge-eating disorder and does not report any pharmacokinetic parameters. |
| PGx | Guzman_2014 | not_relevant | 0 | 0 | The text is a general introduction to a review article and does not report specific pharmacogenomic effects on PK/PD parameters for sibutramine. |
| popPK | Han_2015 | relevant | 9 | 2 | The paper describes a population PK model for sibutramine metabolites (M1 and M2) in humans, but the specific numeric parameter estimates are located in Table 2, which is not included in the provided evidence. |
| popPK | Hu_1998 | irrelevant | 0 | 0 | The study is an in-vitro electrophysiology investigation of ion channels, not a pharmacokinetic study, and sibutramine is only a comparator agent. |
| popPK | Iwan_2026 | irrelevant | 0 | 0 | The paper focuses on machine learning models for cardiotoxicity prediction using FAERS data and does not report any pharmacokinetic parameters for sibutramine. |
| PD | Iwan_2026 | not_relevant | 0 | 0 | The paper is a machine learning study on drug-induced cardiotoxicity prediction using pharmacovigilance data and does not report any pharmacokinetic or pharmacodynamic parameters, exposure-response relationships, or dose-effect curves for sibutramine. |
| popPK | Kaptein_2012 | irrelevant | 0 | 0 | The paper analyzes weight loss efficacy using an exponential model, not pharmacokinetic disposition parameters for sibutramine. |
| PD | Kaptein_2012 | not_relevant | 2 | 1 | The paper fits a time-course exponential model to mean weight data to estimate maximum weight loss and duration, but does not report a concentration- or dose-response relationship with numeric PD parameters (e.g., EC50, Emax vs. dose/concentration) for sibutramine. |
| popPK | Kilpatrick_2001 | irrelevant | 0 | 0 | The paper is an in-vitro mechanistic study on monoamine oxidase inhibition and does not report any pharmacokinetic parameters for sibutramine. |
| popPK | Kim_2007 | irrelevant | 0 | 0 | The paper describes in-vitro ion channel blocking mechanisms of sibutramine and does not report pharmacokinetic parameters. |
| popPK | Kim_2008 | irrelevant | 0 | 0 | The paper title indicates an electrophysiological safety study, which is not a pharmacokinetic study reporting quantitative disposition parameters. |
| PD | Kim_2008 | not_relevant | 0 | 0 | The paper focuses on electrophysiological safety (QT interval) and does not report a pharmacodynamic exposure-response or dose-response model with numeric PD parameters for sibutramine. |
| popPK | Kim_2009_2 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of hERG channel blockade, not a pharmacokinetic study reporting disposition parameters. |
| popPK | Lu_2024 | irrelevant | 0 | 0 | The paper describes an immunoassay method for detection, not a pharmacokinetic study, and contains no PK parameters. |
| PD | Lu_2024 | not_relevant | 0 | 0 | The paper describes an analytical method (ELISA) for detecting sibutramine and methyl parathion, not a pharmacodynamic or exposure-response study. |
| PGx | Luque_1999 | not_relevant | 0 | 0 | The paper is a general review of sibutramine's pharmacology and efficacy, with no mention of gene variants or pharmacogenomic effects on PK/PD parameters. |
| popPK | Metzger_2010 | irrelevant | 0 | 0 | The paper is a pharmacodynamic study on body temperature in mice where sibutramine is used only as a comparator agent, with no pharmacokinetic parameters reported. |
| PD | Metzger_2010 | not_relevant | 1 | 0 | The paper describes a qualitative pharmacodynamic assay (body temperature) for sibutramine but does not provide numeric concentration-effect data, dose-response curves, or PD parameters (Emax, EC50) for sibutramine in the provided text. |
| popPK | Mika_2022 | irrelevant | 0 | 0 | The study investigates the anti-obesity effects of novel histamine H3 receptor ligands (KSK-60 and KSK-74) in rats and does not involve sibutramine or its pharmacokinetics. |
| PD | Mika_2022 | not_relevant | 0 | 0 | The paper studies new compounds (KSK-60, KSK-74) and does not report any pharmacodynamic or exposure-response data for sibutramine. |
| PGx | Mo_2009 | not_relevant | 0 | 0 | The paper is a general review of CYP2B6 and mentions sibutramine only as a substrate, without reporting specific pharmacogenomic effects on its PK or PD parameters. |
| PGx | Morikawa_2017 | not_relevant | 0 | 0 | The paper investigates the cellular mechanism of sibutramine toxicity and the role of CYP3A4 in cytotoxicity, but does not report pharmacogenomic effects on PK or PD parameters in humans. |
| popPK | Persky_2004 | irrelevant | 2 | 0 | The study focuses on acute pharmacodynamic responses (metabolic rate, heart rate, etc.) rather than quantitative pharmacokinetic disposition parameters like clearance or volume. |
| PD | Persky_2004 | not_relevant | 3 | 2 | The study reports qualitative changes in pharmacodynamic markers (e.g., increased resting metabolic rate) for a single dose of sibutramine but does not provide numeric PD parameters (Emax, EC50) or a concentration-effect curve. |
| PGx | Rege_2008 | not_relevant | 0 | 0 | The paper is a review of antipsychotic-induced weight gain and does not report pharmacogenomic effects on the PK or PD of sibutramine. |
| popPK | Richardson_2006 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of lipolysis in adipocytes, not a pharmacokinetic study reporting disposition parameters. |
| PGx | Sardela_2018 | not_relevant | 0 | 0 | The paper describes a zebrafish water tank model for drug metabolism and does not report human pharmacogenomic effects on sibutramine PK/PD parameters. |
| popPK | Shao_2021 | irrelevant | 0 | 0 | The paper is a bibliometric review of electrochemical sensors for tea components and does not contain any pharmacokinetic data for sibutramine. |
| PD | Shao_2021 | not_relevant | 0 | 0 | The paper is a bibliometric review of electrochemical sensors for tea analysis and contains no pharmacodynamic or exposure-response data for sibutramine. |
| PGx | Shinde_2014 | not_relevant | 0 | 0 | The study examines enantioselective metabolism in vitro using recombinant CYPs and microsomes, but does not report pharmacogenomic effects of specific gene variants on PK/PD parameters in humans. |
| popPK | Somogyi_2012 | irrelevant | 0 | 0 | no_text gate: only 18 chars of text extracted (&lt; 400) |
| PD | Somogyi_2012 | not_relevant | 0 | 0 | The text is an editorial review that mentions sibutramine only in the context of illicit drug poisoning cases and does not report any pharmacodynamic or exposure-response data. |
| popPK | Spahn_2025 | irrelevant | 0 | 0 | The paper is a white paper on pharmacovigilance and pharmacogenomics and does not contain any pharmacokinetic data or parameters for sibutramine. |
| PD | Spahn_2025 | not_relevant | 0 | 0 | The paper is a white paper on pharmacovigilance and pharmacogenomics; it mentions sibutramine only as an example of a drug withdrawal due to safety concerns, without reporting any pharmacodynamic or exposure-response data. |
| popPK | Subhan_2000 | irrelevant | 0 | 0 | The study is a behavioral pharmacology experiment (conditioned place preference) in rats and does not report any pharmacokinetic parameters for sibutramine. |
| popPK | Sutherland_2023 | irrelevant | 0 | 0 | The paper is an in vitro pharmacology resource describing off-target activities and adverse drug reactions, not a pharmacokinetic study reporting disposition parameters for sibutramine. |
| PD | Sutherland_2023 | not_relevant | 0 | 0 | The paper reports in vitro secondary pharmacology (AC50) and safety margins (ratio of AC50 to Cmax) for a database of drugs, but does not report a pharmacodynamic model (e.g., Emax, EC50) or exposure-response relationship for sibutramine specifically. |
| PGx | Vrzal_2013 | not_relevant | 0 | 0 | The paper investigates the effect of sibutramine on CYP expression, not the effect of a gene variant on sibutramine's PK/PD. |
| PGx | Wang_2015 | not_relevant | 0 | 0 | The paper is a review of drug-drug interactions involving clopidogrel; while it mentions sibutramine as a victim drug, it does not report pharmacogenomic effects (gene variants) on sibutramine's PK/PD parameters. |
| popPK | Wang_2025 | irrelevant | 0 | 0 | The study focuses on pharmacodynamic efficacy (weight loss) rather than pharmacokinetic disposition parameters for sibutramine. |
| PD | Wang_2025 | not_relevant | 3 | 2 | The paper is a meta-analysis of clinical trial outcomes (weight loss in kg) rather than a pharmacokinetic/pharmacodynamic study; it reports efficacy endpoints and time-to-plateau but does not provide exposure-response data, concentration-effect curves, or specific PD parameters like Emax or EC50 for sibutramine. |
| popPK | Wortley_1999 | irrelevant | 0 | 0 | The study is an in vivo microdialysis pharmacodynamic study measuring extracellular noradrenaline concentrations, not a pharmacokinetic study reporting disposition parameters like clearance or volume. |
| popPK | Yun_2015 | irrelevant | 0 | 0 | The study focuses on cardiovascular safety pharmacology (hERG, APD, telemetry) and does not report pharmacokinetic disposition parameters such as clearance, volume, or half-life. |
| popPK | de_2014 | irrelevant | 0 | 0 | The study is a pharmacodynamic investigation of sympathetic neurotransmission in rat vas deferens and does not report any pharmacokinetic parameters for sibutramine. |
| popPK | unknown_2015 | irrelevant | 0 | 0 | The paper is a clinical trial regarding binge-eating disorder treatment outcomes and does not report pharmacokinetic parameters for sibutramine. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
